Hospira Acquires EndoTool From MD Scientific
13 Outubro 2008 - 1:14PM
PR Newswire (US)
- Innovative glucose control management system helps enhance
quality of care and patient safety - LAKE FOREST, Ill., Oct. 13
/PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE:HSP), a global
specialty pharmaceutical and medication delivery company, announced
today that it has acquired the EndoTool(R) business from MD
Scientific, LLC. The EndoTool glucose management system, a highly
sophisticated software system cleared by the U.S. Food and Drug
Administration (FDA), helps establish and maintain glycemic control
in acute, critical care and operating room settings by calculating
the dose of intravenous (I.V.) insulin needed to effectively
control blood glucose levels. Hospira is demonstrating EndoTool at
the American Nurses' Credentialing Center (ANCC) National Magnet
Conference, Oct. 15 - 17, in Salt Lake City. "This acquisition
represents an important extension of Hospira's commitment to
improved outcomes, patient safety and enhanced clinician
efficiency," said Chris Kolber, president, Global Devices, Hospira.
"With the market-leading EndoTool in the Hospira portfolio, we are
underscoring our commitment to technological leadership in the
important area of clinical-decision support systems."
Traditionally, nurses and other clinicians use paper-based
protocols to manually monitor and adjust I.V. insulin dosing. The
EndoTool software system is easy to operate, runs on a hospital's
existing computer system and can interface with a hospital
information system (HIS). EndoTool actively models and adapts to
individual patient responses to I.V. insulin to help manage current
and predict future dosage levels. It is the only software that uses
five separate data points -- based on the patient's most recent
blood glucose readings -- to provide personalized, safe and
effective glycemic control. Integrating more than 30 unique
algorithms (mathematical steps) into its dosage calculation method,
EndoTool helps ensure an extremely low incidence of hypoglycemia
(low blood glucose) by automating and standardizing the practice of
glucose management. "After using EndoTool in one of our hospitals
as a pilot, we observed better and safer glucose control and
improved patient outcomes," said Loran Hauck, M.D., senior vice
president and chief medical officer, at Florida-based Adventist
Health System. "We then moved to install EndoTool in the ICUs at
every hospital in our system. In the future we plan to use EndoTool
in the operating rooms, emergency department, obstetrical units and
step-down units across our ten-state, 37-hospital health system."
To date, more than 10,000 patients with more than 450,000 blood
glucose readings have had their blood glucose levels controlled
with EndoTool. In acute and critical-care settings, effective blood
glucose management is integral to high-quality, safe patient care.
Maintaining the appropriate precision to avoid under-or over-dosing
of insulin is essential to improved patient management. For
example, overly aggressive insulin therapy can increase the risk of
hypoglycemia, which is an independent risk factor for
mortality.(1,2) Whereas, complications of hyperglycemia (high blood
glucose) include increased morbidity and mortality; as well as
increased risk of secondary infection, impaired immune function and
delayed wound healing.(1,3,4) The EndoTool customer base includes
leading healthcare institutions in both community and academic
settings, including many Magnet accredited hospitals. Magnet status
is given by the ANCC, an affiliate of the American Nurses
Association, to hospitals that satisfy a set of criteria designed
to measure the strength and quality of their nursing. As part of
the agreement, Hospira acquired additional assets related to the
EndoTool business, including the MD Scientific headquarters in
Charlotte, N.C., and the employees supporting the product.
Financial details of the agreement were not disclosed. About MD
Scientific MD Scientific, LLC, headquartered in Charlotte, N.C.,
was formed in 2003 with the mission of introducing physician
innovation to improve healthcare. About Hospira Hospira, Inc. is a
global specialty pharmaceutical and medication delivery company
dedicated to Advancing Wellness(TM). As the world leader in
specialty generic injectable pharmaceuticals, Hospira offers one of
the broadest portfolios of generic acute-care and oncology
injectables, as well as integrated infusion therapy and medication
management solutions. Through its products, Hospira helps improve
the safety, cost and productivity of patient care. The company is
headquartered in Lake Forest, Ill., and has more than 14,000
employees. Learn more at http://www.hospira.com/. Private
Securities Litigation Reform Act of 1995 -- A Caution Concerning
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Hospira cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Economic,
competitive, governmental, technological and other factors that may
affect Hospira's operations and may cause actual results to be
materially different from expectations include the risks,
uncertainties and factors discussed under the headings "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Hospira's latest Annual
Report on Form 10-K, and Hospira's subsequent Quarterly Reports on
Form 10-Q, which are filed with the Securities and Exchange
Commission, and incorporated by reference. Hospira undertakes no
obligation to release publicly any revisions to forward-looking
statements as the result of subsequent events or developments. (1)
Van den Berghe G, et al. N Engl J Med 2006;354:449-61. (2) Krinsley
JS, et al. Crit Care Med 2007;35:2262-7. (3) Van den Berghe G, et
al. N Engl J Med 2001;345:1359-67. (4) Inzucchi SE, et al. N Engl J
Med 2006;355:1903-11.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Media, Tareta Adams, +1-224-212-2535, or Financial Community, Karen
King, +1-224-212-3323, both of Hospira, Inc. Web site:
http://www.hospira.com/
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024